Morbidity and mortality on maintenance haemodialysis

Contributions to Nephrology

Volumn 124, Issue , 1998, Pages 166-201

  Locatelli, Francesco ^a   Del Vecchio, Lucia ^a   Manzoni, Celestina ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Dialysis membranes; Dialysis patient; Dialysis registries; Dose and duration of dialysis; Morbidity and mortality; rEPO and survival

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; COMORBIDITY; FEMALE; HOSPITAL SERVICE; HUMAN; ITALY; KIDNEY FUNCTION TEST; MALE; METHODOLOGY; MIDDLE AGED; MORBIDITY; MORTALITY; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SEX DIFFERENCE; SURVIVAL;

ADULT; AGE DISTRIBUTION; AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; FEMALE; HUMANS; ITALY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MAINTENANCE; MALE; MIDDLE AGED; MORBIDITY; RENAL DIALYSIS; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 0032238832     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000059936     Document Type: Article

References (115)

1. Locatelli F, Marcelli D, Conte F: Dialysis patient outcomes in Europe vs. the USA. Why do Europeans live longer? Nephrol Dial Transplant 1997;12:1816-1819.
2. Marcelli D, Stannard D, Conte F, Held PJ, Locatelli F, Port FK: ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the USA. Kidney Int 1996;50:1013-1018.
3. Marcelli D, Spotti D, Conte F, Tagliaferro A, Limido A, Lonati F, Malberti F, Locatelli F: Survival of diabetics patients on peritoneal dialysis or haemodialysis. Perit Dial Int 1996;16(suppl 1):S283-S287.
4. Byrne C, Vernon P, Cohen JJ: Effect of age and diagnosis on survival of older patients beginning chronic dialysis. JAMA 1994;271:34-36.
5. Nelson CB, Port FK, Wolfe RA, Guire KE: The association of diabetic status, age and race to withdrawal from dialysis. J Am Soc Nephrol 1994;4:1608-1614.
6. Lowrie EG, Lew NL, Huang WH: Race and diabetes as death predictors in haemodialysis patients. Kidney Int 1992;38(suppl):S22-S31.
7. Foley RN, Parfrey PS: Cardiac disease in the diabetic dialysis patient. Nephrol Dial Transplant 1998;13:1112-1113.
8. Mailloux LU, Bellucci AG, Napolitano B, Mossey T, Wilkes BM, Bluestone PA: Survival estimates for 683 patients starting dialysis from 1970 through 1989: Identification of risk factors for survival. Clin Nephrol 1994;42:127-135.
9. Zeier M, Jones E, Ritz E: Autosomal dominant polycystic kidney disease - The patient on renal replacement therapy. Nephrol Dial Transplant 1996;11(suppl 6):18-20.
10. Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A: Northern Italian Cooperative Study Group. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Lancet 1991;337:1299-1304.
11. Wu MS, Yu CC, Yang CW, Wu CH, Haung JY, Hong JJ, Fan Chiang CY, Huang CC, Leu ML: Poor pre-dialysis glycemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 1997;12:2105-2110.
12. Innes A, Rowe PA, Burden RP, Morgan AG: Early deaths on renal replacement therapy: The need for early nephrological referral. Nephrol Dial Transplant 1992;7:467-471.
13. Campbell JD, Ewigman B, Hosokawa M, Van Stone JC: The timing of referral of patients with end-stage renal disease. Dial Transplant 1989;18:660-686.
14. Jungers P, Skhiri H, Zingraff J, Muller S, Fumeron C, Giatras I, Touam M, Nguyen AT, Man NK, Grunfeld JP: Benefits of early nephrological management of chronic renal failure. Presse Med 1997; 26:2-5.
15. Lameire N: The referral pattern of patients with ESRD is a determinant in the choice of dialysis modality. Perit Dial Int 1997;17(suppl 2):S161-S166.
16. Sesso R, Belasco AG: Late diagnosis of chronic renal failure and mortality on maintenance dialysis. Nephrol Dial Transplant 1996;11:2417-2420.
17. USA Renal Data System 1997 annual data report: The USRDS Dialysis Morbidity and Mortality Study: Wave 2. Am J Kidney Dis 1997;30(suppl 1):S67-S85.
18. D'Amico G: Comparability of the different registries on renal replacement therapy. Am J Kidney Dis 1995;25:113-118.
19. Friedman EA: Health care reform engulfs all of us. Nephrol Dial Transplant 1996;11:1881-1884.
20. National High Blood Pressure Education Program Working Group: Report on hypertension and chronic renal failure. Arch Intern Med 1991;151:1280-1287.
21. Levey M, Meltzer D: Does reduction in cardiovascular death account for the increase in ESRD? An examination of the 'Competitive Mortality' hypothesis (abstract). J Am Soc Nephrol 1996;7:1392.
22. Bonomini V, Vangelista A, Stefoni S: Early dialysis in renal substitutive programs. Kidney Int 1978; 13(suppl 8):S112-S116.
23. US Department of Health and Human Services. Health Care Financing Administration: End-stage renal disease medical evidence report: Medicare entitlement/or patient registration. HCFA-2778-U4(4-95).
24. Tattersall JE, Greenwood RN, Farrington K: Urea kinetics and when to commence dialysis. Am J Nephrol 1995;15:283-289.
25. Ifudu O, Dawood M, Homel P, Friedman EA: Timing of initiation of uraemia therapy and survival in patients with progressive renal disease. Am J Nephrol 1998;18:193-198.
26. Ismail N, Hakim RM, Oreopoulus DG, Patrikarea A: Renal replacement therapies in the elderly. 1. Hemodialysis and chronic peritoneal dialysis. Am J Kidney Dis 1993;22:759-782.
27. Brunner FP, Selwood NH: Profile of patients on RRT in Europe and death rates due to major causes of death groups. Kidney Int 1992;42:S4-S15.
28. Locatelli F, Marcelli D, Conte F, Limido A, Lonati F, Malberti F, Spotti D: 1983 to 1992: Report on regular dialysis and transplantation in Lombardy. Am J Kidney Dis 1995;25:196-205.
29. 1996 Annual Report of Registro Lombardo Dialisi Trapianto, Regione Lombardia, Direzione Generale Sanità, Milan, Dec 18, 1997.
30. Port FK: The end-stage renal disease program: Trends over the past 18 years. Am J Kidney Dis 1992;20:30-37.
31. Bloembergen WE, Port FK, Mauger EA, Wolfe RA: Causes of death in dialysis patients: Racial and gender differences. J Am Soc Nephrol 1994;5:1231-1242.
32. USA Renal Data System 1997 annual data report. Am J Kidney Dis 1997;30(suppl 1):S1.
33. Valderràbano F, Berthoux FC, Jones HHP, Mehls O: Report on management of renal failure in Europe, XXV, 1994. End-stage renal disease and dialysis report. Nephrol Dial Transplant 1996; 11(suppl 1):2-21.
34. Teraoka S, Toma H, Nihei H, Ota K, Babazono T, Shinoda A, Maeda K, Koshikawa S, Takahashi T: Current status of renal replacement therapy in Japan. Am J Kidney Dis 1995;25:151-164.
35. Agodoa LY, Eggers PW: Renal replacement therapy in the USA: Data from the USA Renal Data System. Am J Kidney Dis 1995;25:119-133.
36. Fenton S, Desmeules M, Copleston P, Arbus G, Froment D, Jeffery J, Kjellstrand C: Renal replacement therapy in Canada: A report from the Canadian Organ Replacement Register. Am J Kidney Dis 1995;25:134-150.
37. Kopple JD, Levey AS, Greene T, Chumlea WC, Gassman JJ, Hollinger DL, Maroni BJ, Merril D, Scherch LK, Schulman G, Wang SR, Zimmer GS: Effect of dietary protein restriction on nutritional status in the modification of diet renal disease study. Kidney Int 1997;52:778-791.
38. Malberti F, Conte F, Limido A, Marcelli D, Spotti D, Lonati F, Locatelli F: Ten years experience of renal replacement therapy in the elderly. Geriatr Nephrol Urol 1997;7:1-10.
39. Port FK: Morbidity and mortality in dialysis patients. Kidney Int 1994;46:1728-1737.
40. Neff MS, Eiser AR, Slifkin RF, Baum M, Baez A, Gupta S, Amarga E: Patients surviving 10 years of haemodialysis. Am J Med 1983;74:996-1004.
41. Salem MM, Bower J: Hypertension in haemodialysis population: Any relation to one-year survival? Am J Kidney Dis 1996;28:737-740.
42. Duranti E, Imperiali P, Sasdelli M: Is hypertension a mortality risk factor in dialysis? Kidney Int 1996;55:S173-S174.
43. Kimura G, Tomita J, Nakamura S, Uzu T, Inenaga T: Interaction between hypertension and other cardiovascular risk factors in survival of hemodialysed patients. Am J Hypertens 1996;9:1006-1012.
44. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre P: Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996;49:1379-1385.
45. Cannella G, Paoletti E, Delfineo R, Peloso G, Molinari S, Traverso GB: Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 1993;44:881-886.
46. Charra B: Control of blood pressure in long slow haemodialysis. Blood Purif 1994;12:252-258.
47. Charra B: Dialysis Time. What it should be? ASAIO J 1997;43:228-229.
48. Raine AEG, MacMahon SH, Selwood NH, Wing AJ, Brunner FP: Mortality from myocardial infarction in patients on renal replacement therapy in the UK. Nephrol Dial Transplant 1991;6:902-910.
49. Parfrey PS, Harnett JD, Foley RN: Heart failure and ischaemic heart disease in chronic uraemia. Curr Opin Nephrol Hypertens 1995;4:105-110.
50. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192.
51. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfery PS: Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47:884-890.
52. Silberg JS, Barre PE, Prichard SS, Snidermann SD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36:286-290.
53. Washio M, Okuda S, Mizoue T, Kiyama S, Ando T, Sanai T, Hirakata H, Nanishi F, Kiyohara C, Ogimoto I, Yoshimura T, Fujishima M: Risk factors for left ventricular hypertrophy in chronic haemodialysis patients. Clin Nephrol 1997;47:362-366.
54. Parfrey PS, Griffiths SM, Harnett JD, Taylor R, King A, Hand J, Barre PE: Outcome of congestive heart failure, dilated cardiomyopathy, hypertrophic hyperkinetic disease, and ischemic heart disease in dialysis patients. Am J Nephrol 1990;10:213-221.
55. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF: Anaemia in haemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 1997;8:1921-1929.
56. Collins A, Ma J: Early haematocrit correction improves patient survival (abstract). Nephrology 1997;3(suppl 1):S187.
57. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anaemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
58. Iseki K, Nishimec K, Uehara H, Tokuyama K, Toma S, Yoshihara K, Kowatari T, Terukina S, Osawa A, Fukiyama K: Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron 1996;72:30-36.
59. Evans SJ: Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron 1997;76:116.
60. Locatelli F, Conte F, Marcelli D: The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - The experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 1998;13:1642-1644.
61. Möcks J: Analysis of safety database for long-term epoietin-beta treatment. A meta-analysis covering 3,697 patients; in Koch, Stein (eds): Pathogenetic and Therapeutic Aspects of Chronic Renal Failure, chap 12. New York, Dekker 1997, pp 163-179.
62. Eschbach JW, Aquiling T, Haley NR, Fan MH, Blagg CR: The long-term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 1992;38(suppl 1):98-103.
63. Anemia Work Group for National Kidney Foundation - Dialysis Outcomes Quality Initiative (NKF-DOQI): Clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997;30(suppl 3):192-240.
64. Marçen R, Teruel JL, Angel de la Cal M, Gàmez C and the Spanish Cooperative Study of Nutrition in Hemodialysis: The impact of malnutrition in morbidity and mortality in stable haemodialysis patients. Nephrol Dial Transplant 1997;12:2324-2331.
65. Goldwasser P, Mittman N, Antignani A, Burrel D, Michel MA, Collier J, Avram MM: Predictors of mortality in haemodialysis patients. J Am Soc Nephrol 1993;3:1613-1622.
66. Churchill DN, Taylor DW, Cook RJ, LaPlante P, Barre P, Cartier P, Fay WP, Goldstein MB, Jindal K, Mandin H, McKenzie JK, Muirhead N, Parfery PS, Posen GA, Slaughter D, Ulah RA, Werb R: Canadian haemodialysis morbidity study. Am J Kidney Dis 1992;3:214-234.
67. Iseki K, Kawazoe N, Fukiyama K: Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int 1993;44:115-119.
68. Lowrie EG, Lew LN: Death risk in haemodialysis patients: The predictive value of commonly measured variables and evaluation of death rates differences between facilities. Am J Kidney Dis 1990;15:458-482.
69. Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing haemodialysis. N Engl J Med 1993; 329:1001-1006.
70. Bergström J: Nutrition and mortality in haemodialysis. J Am Soc Nephrol 1995;6:1329-1341.
71. Capelli JP, Kushner H, Camiscioli TC, Chen SM, Torres MA: Effect of intradialytic parenteral nutrition on mortality rates in end-stage renal disease care. Am J Kidney Dis 1994;23:808-816.
72. Foley RN, Parfrey PS, Harnett JD, Kent GM, Hu L, O'Dea R, Murray DC, Barre PE: Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 1996;16:386-393.
73. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic haemodialysis patients: A national study. Am J Kidney Dis 1998;31:607-617.
74. Parfrey PS, Harnett JD, Griffiths SM, Gault MH, Barre PE, Guttmann RD: Low-output left ventricular failure in end-stage renal disease. Am J Nephrol 1987;7:184-191.
75. London GM, Fabiani F, Marchais SJ, de Vernejoul MC, Guerin AP, Safar ME, Metivier F, Llach F: Uremic cardiomyopathy: An inadequate left ventricular hypertrophy. Kidney Int 1987;31:973-980.
76. Polashegg HD: Automatic non-invasive intradialytic clearance measurements. Int J Artif Organs 1993;16:185-191.
77. Peticlerc T, Goux N, Reynier AL, Béné B: A model for non-invasive estimation of in-vivo dialyzer performances and patient's conductivity during haemodialysis. Int J Artif Organs 1993;16:585-591.
78. Locatelli F, Di Filippo S, Manzoni C, Corti M, Andrulli S, Pontoriero G: Monitoring sodium removal and delivered dialysis by conductivity. Int J Artif Organs 1995;18:716-721.
79. Di Filippo S, Corti M, Andrulli S, Pontoriero G, Manzoni C, Locatelli F: Optimization of sodium removal in paired filtration dialysis by single pool sodium and conductivity kinetic models. Blood Purif 1997;15:34-44.
80. Locatelli F, Andrulli S, Di Filippo S, Redaelli B, Mangano S, Navino C, Ariano R, Tagliaferri M, Fidelio T, Corti M, Civardi S, Tetta C: Effect of on-line conductivity plasma ultrafiltrate kinetic modelling on cardiovascular stability of haemodialysis patients. Kidney Int 1998;53:1052-1060.
81. Redaelli B, Locatelli F, Limido D, Andrulli S, Signorini MG, Sforzini S, Bonoldi L, Vincenti A, Cerutti S, Orlandini G: Effect of a new model of haemodialysis potassium removal on the control of ventricular arrhythmias. Kidney Int 1996;50:609-617.
82. Churchill DN, Wayne Taylor D, Tomlinson CW, Beecroft ML, Gorman J, Stanton E: Effect of high-flux haemodialysis on cardiac structure and function among patients with end-stage renal failure. Nephron 1993;65:573-577.
83. Woods HF: Evidence for a biocompatibility-independent effect of high-flux dialysis on improved patient survival (abstract). Nephrology 1997;3(suppl 1):S415.
84. Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, Agodoa L: Effect of the dialysis membrane on mortality of chronic haemodialysis patients. Kidney Int 1996;50:566-570.
85. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of haemodialysis patients. Kidney Int 1997;52:1096-1101.
86. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, Orlandini G and the Italian Cooperative Dialysis Study Group: Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. Kidney Int 1996;50:1293-1302.
87. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D: Morbidity and mortality in ESRD patients on convective or on diffusive extracorporeal treatment (abstract). Nephrol Dial Transplant 1997;12:A174.
88. 2-microglobulin amyloidosis in haemodialysis: A prospective post-mortem study. Kidney Int 1997;52:1928-1932.
89. Van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J and the Working Party on Dialysis Amyloidosis: Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. Kidney Int 1991;39:1012-1019.
90. Kuchle C, Fricke H, Held E, Schiffl H: High-flux haemodialysis postpones clinical manifestation of dialysis- related amyloidosis. Am J Nephrol 1996;16:484-488.
91. 2-microglobulin levels in chronic haemodialysis patients. J Am Soc Nephrol 1996;7:472-478.
92. Gotch FA, Sargent JA: A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985;28:526-534.
93. Hakim RM, Breyer J, Ismail N, Schulman G: Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994;23:661-669.
94. Parker TF, Husni L, Huang W, Lew N, Lowrie E: Survival of haemodialysis in the US is improved with a greater quantity of dialysis. Am J Kidney Dis 1994;23:670-680.
95. Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, Bloembergen WE, Greer JW, Hakim RM: The dose of haemodialysis and patient mortality. Kidney Int 1996;50:550-556.
96. Sargent JA, Gotch FA: Principles and biophysics of dialysis; in Drukker W, Parsons FM, Maher JF (eds): Replacement of Renal Function by Dialysis. Boston, Nijhoff, 1983, pp 53-96.
97. Smye SW, Dunderdale E, Brownridge G, Will E: Estimation of treatment dose in high-efficiency haemodialysis. Nephron 1994;67:24-29.
98. Daugirdas JT, Schneditz D: Overestimation of haemodialysis dose (DKt/V) depends on dialysis efficiency (K/V) by regional blood flow and conventional two-pool urea kinetic analyses. ASAIO J 1995;41:M719-M724.
99. Gotch F, Peter H, Panlilio F, Folden T, Keen M: On-line measurement of delivered KT/V during dialysis (abstract). J Am Soc Nephrol 1995;6:600.
100. Ebben J, Ruan J, Keshaviah P, Emerson P: Sodium (conductivity) dialysance is membrane dependent. Abstracts of 42nd Annual Conference of ASAIO, Washington 1996, p 81.
101. Manzoni C, Di Filippo S, Corti M, Locatelli F: Ionic dialysance as a method for the on-line monitoring of delivered dialysis without blood sampling. Nephrol Dial Transplant 1996;11:2023-2030.
102. Di Filippo S, Andrulli S, Manzoni C, Corti M, Locatelli F: On-line assessment of delivered dialysis dose. Kidney Int 1998;54:263-267.
103. Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA: Hemodialysis vascular access morbidity in the USA. Kidney Int 1993;43:1091-1096.
104. Sehgal AR, Snow RJ, Singer ME, Amini SB, DeOreo PB, Silver MR, Cebul RD: Barriers to adequate delivery of haemodialysis. Am J Kidney Dis 1998;31:593-601.
105. Nielsen J, Kolmos HJ, Espersen F: Staphylococcus aureus bacteraemia among patients undergoing dialysis: Focus on catheter-related cases. Nephrol Dial Transplant 1998;13:139-145.
106. Held PJ, Brunner F, Okada M, Garcia JR, Port FK, Gaylin DS: Five-year survival for end-stage renal disease patients in the USA, Europe and Japan, 1982 to 1987. Am J Kidney Dis 1990;15:451-457.
107. Held PJ, Blagg CR, Liska DW, Port FK, Hakim R, Levin N: The dose of haemodialysis according to dialysis prescription in Europe and USA. Kidney Int 1992;42:S16-S21.
108. Kimmel PL, Weish K, Peterson RA: Survival in haemodialysis patients: The role of depression. J Am Soc Nephrol 1993;4:12-27.
109. Laurent G: How to keep the dialysis patients normotensive? What is the secret of Tassin? Nephrol Dial Transplant 1997;12:1104.
110. Charra B: 'Dry weight' in dialysis: The history of a concept. Nephrol Dial Transplant 1998;13:1882-1885.
111. Collins AJ, Keane WF: Higher haematocrit levels: Do they improve patient outcomes, and are they cost effective? Nephrol Dial Transplant 1998;13:1627-1629.
112. Bloembergen WE, Stannard DC, Port FK, Wolfe RA, Pugh JA, Jones CA, Greer JW, Golper TA, Held PJ: Relationship of dose of haemodialysis and cause-specific mortality. Kidney Int 1996;50:557-565.
113. Haag-Weber M, Horl WH: Effect of biocompatible membranes on neutrophil function and metabolism. Clin Nephrol 1994;42(suppl 1):S31-S36.
114. 2-Microglobulin-associated amyloidosis: A vanishing complication of long-term haemodialysis? Kidney Int 1997;52:1077-1083.
115. Buccianti G, Maisonneuve P, Ravasi B, Cresseri D, Locatelli F, Boyle P: Cancer among patients on renal replacement therapy: A population-based survey in Lombardy, Italy. Int J Cancer 1996;66:591-593.